Global COVID-19 Infection Market, By Type (Omicron, Delta, Gamma, Beta, Alpha), Treatment (Medication, Vaccine, Others), Diagnosis (Swab Test, Antibody Test, Others), Dosage Forms (Capsule, Tablets, Injections, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
The World Health Organization classified SARS-CoV-2 as a novel coronavirus type in early 2020, following a December 2019 epidemic in China. The epidemic soon spread around the globe. SARS-CoV-2 causes COVID-19, a condition that causes a respiratory tract infection, according to specialists. It can affect either the upper or lower respiratory system. Vaccines for youngsters as young as 5 years old are now available. These vaccines contain a third of the dose of the Pfizer-BioNTech COVID-19 vaccine, which is approved for children aged 12 and up. The children's version, such as the adult version, takes two does spaced three weeks apart. Adults can also have a two-dose Moderna vaccine or a single-dose Johnson & Johnson vaccine.
Data Bridge Market Research analyses that the COVID-19 infection market was valued at USD 18.69 billion in 2021 and is expected to reach USD 48.99 billion by 2029, registering a CAGR of 12.80% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Omicron, Delta, Gamma, Beta, Alpha), Treatment (Medication, Vaccine, Others), Diagnosis (Swab Test, Antibody Test, Others), Dosage Forms (Capsule, Tablets, Injections, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Serum Institute of India Pvt. Ltd. (India), Bharat Biotech (India), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), Hikma Pharmaceuticals PLC (U.K.), Genentech Inc. (U.S.), Zydus Cadila (India)
|
|
Market Opportunities
|
|
Market Definition
Coronaviruses are a type of virus that can infect humans and cause respiratory illnesses. Because of the crown-like spikes on the virus's surface, they're known as "corona." Coronaviruses that cause sickness in humans include SARS, MEERS, and the common cold. The antiviral medication remdesivir (Veklury) has been approved by the FDA to treat COVID-19 in hospitalized adults and children aged 12 and up. Remdesivir may be administered for COVID-19 patients who require supplementary oxygen or are at a higher risk of serious disease. It's injected into the skin with a needle (intravenously). A vaccine can help you avoid contracting the COVID-19 virus or keep you from becoming extremely ill if you do contract it.
COVID-19 Infection Market Dynamics
Drivers
- Lack of awareness and safety among people
The dearth of awareness and safety among people is estimated to enhance the COVID-19 infection market's growth rate. COVID-19 is caused by the SARS-CoV-2 virus, which enters the body by the mouth, nose, or eyes (directly from the airborne droplets or from the transfer of the virus from your hands to your face). The mucus membrane in the back of your throat and the rear of your nasal passages are where it goes next. It clings to the cells in the area, multiplies, and spreads into the lung tissue. The virus can then spread to other tissues in the body.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of COVID-19 infection market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Rising geriatric population
One of the primary reasons driving revenue growth in the COVID-19 infection market is the ageing population. People over the age of 65, and those with underlying medical disorders including cardiovascular disease, diabetes, chronic respiratory disease, or cancer, are more prone to developing chronic infections. COVID-19 can make anyone sick, causing serious illness or death, at any age.
Furthermore, increasing incidences of obesity and sedentary lifestyle of people such as growing addiction of smoking will expand the COVID-19 infection market. Additionally, growing government initiatives to spread awareness and presence of favorable reimbursement policies are estimated to enhance the market’s growth rate.
Opportunities
- Increase in the number of research and development activities
The COVID-19 infection market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the COVID-19 infection market growth.
Moreover, increase in the number of emerging markets and rising technological advancement will further provide beneficial opportunities for the COVID-19 infection market growth during the forecast period.
Restraints/Challenges
On the other hand, high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the COVID-19 infection market. Additionally, side effects linked with vaccine such as fever, fatigue, headache, and others and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This COVID-19 infection market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the COVID-19 infection market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
COVID-19 infection market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Recent Development
- In December 2021, the U.S. Food and Drug Administration had announced the emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for treating mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
Global COVID-19 Infection Market Scope
The COVID-19 infection market is segmented on the basis of type, treatment, diagnosis, dosage forms, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Omicron
- Delta
- Gamma
- Beta
- Alpha
Treatment
- Medication
- Malaria drugs
- Hydroxychloroquine
- Chloroquine
- Antiviral drug
- Remdesivir
- Analgesic drugs
- Ibuprofen
- Acetaminophen
- Others
- Vaccine
- Comirnaty vaccine
- COVISHIELD
- Moderna
- Sinovac-CoronaVac vaccine
- COVAXIN vaccine
- Covovax vaccine
- Nuvaxovid vaccine
- Others
Diagnosis
- Swab Test
- Antibody Test
- Others
Dosage Forms
- Capsule
- Tablets
- Injections
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Pipeline Analysis
BNT162b2 vaccine, mRNA-1273 vaccine, and Ad26.COV2.S vaccine were created to target the SARS-CoV-2 spike protein main site, where these variations have gained mutations, raising concerns about vaccination efficacy against the new variants.
|
VACCINE
|
PHASE
|
SPONSER
|
|
BNT162b2 vaccine
|
Phase 4
|
Sheba Medical Center (Israel)
|
|
mRNA-1273 vaccine
|
Phase 1
|
National Institute of Allergy and Infectious Diseases (NIAID) (U.S.)
|
|
Ad26.COV2.S vaccine
|
Phase 3
|
Johnson & Johnson Private Limited (U.S.)
|
COVID-19 Infection Market Regional Analysis/Insights
The COVID-19 infection market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, dosage forms, route of administration, end-users and distribution channel as referenced above.
The countries covered in the COVID-19 infection market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the COVID-19 infection market because of the presence of key manufacture of the product and established regulatory framework in this region. Additionally, high demand of diseases specific treatment and surging adoption of newer technologies will further propel the market’s growth rate in this region.
Asia-Pacific is expected to grow during the forecast period due to increased government awareness programs and rising healthcare expenditure in this region. Also, growing number of generic drugs manufacturers will further cushion the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and COVID-19 Infection Market Share Analysis
The COVID-19 infection market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to COVID-19 infection market.
Some of the major players operating in the COVID-19 infection market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Merck & Co., Inc. (U.S.)
- Allergan (Ireland)
- AstraZeneca (U.K.)
- AbbVie Inc. (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Cipla Inc. (U.S.)
- Abbott (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Genentech Inc. (U.S.)
- Zydus Cadila (India)
- Serum Institute of India Pvt. Ltd. (India)
- Bharat Biotech (India)
SKU-